Cerevel Therapeutics
CERE

$44.62

0.45%

Market Cap: 8.13B

About: Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Employees: 355

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

0

News positive %

of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

59% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 49

21% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 34

4% more funds holding

Funds holding: 193 [Q4 2023] → 200 (+7) [Q1 2024]

2% less capital invested

Capital invested by funds: $6.55B [Q4 2023] → $6.44B (-$107M) [Q1 2024]

4% less call options, than puts

Call options by funds: $39M | Put options by funds: $40.6M

1.73% less ownership

Funds ownership: 85.66% [Q4 2023] → 83.93% (-1.73%) [Q1 2024]

10% less funds holding in top 10

Funds holding in top 10: 10 [Q4 2023] → 9 (-1) [Q1 2024]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target

$45

1%

upside

Avg. target

$45

1%

upside

High target

$45

1%

upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

Mizuho

Graig Suvannavejh

1%upside

$45

Neutral

Maintained

16 Feb 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about CERE published over the past 30 days

The Schall Law Firm Is Performing A Scrutiny Into Cerevel Therapeutics Holdings Inc And Proprietors Of CERE Shares Are Welcomed To Engage

LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.

The Schall Law Firm Is Performing A Scrutiny Into Cerevel Therapeutics Holdings Inc And Proprietors Of CERE Shares Are Welcomed To Engage

The Schall Law Firm Is Carrying Out An Inquiry Into Cerevel Therapeutics Holdings Inc And Possessors Of CERE Shares Are Requested To Be Part Of It

LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.

The Schall Law Firm Is Carrying Out An Inquiry Into Cerevel Therapeutics Holdings Inc And Possessors Of CERE Shares Are Requested To Be Part Of It

The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Holders Of CERE Shares Are Encouraged To Participate

LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.

The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Holders Of CERE Shares Are Encouraged To Participate

The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Holders Of CERE Stocks Are Encouraged To Participate

LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.

The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Holders Of CERE Stocks Are Encouraged To Participate

The Schall Law Firm Is Conducting A Probe Into Cerevel Therapeutics Holdings Inc And Shareholders Of CERE Are Invited To Join

LOS ANGELES, CA / ACCESSWIRE / June 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.

The Schall Law Firm Is Conducting A Probe Into Cerevel Therapeutics Holdings Inc And Shareholders Of CERE Are Invited To Join

The Schall Law Firm Is Conducting A Probe Into Cerevel Therapeutics Holdings Inc And Owners Of CERE Shares Are Invited To Join

LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.

The Schall Law Firm Is Conducting A Probe Into Cerevel Therapeutics Holdings Inc And Owners Of CERE Shares Are Invited To Join

CEREVEL (NASDAQ:CERE) ACQUISITION ALERT: Cerevel's $45 Per Share Deal is Being Investigated by BFA Law, Shareholders are Notified to Contact the Firm

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.

CEREVEL (NASDAQ:CERE) ACQUISITION ALERT: Cerevel's $45 Per Share Deal is Being Investigated by BFA Law, Shareholders are Notified to Contact the Firm

The Schall Law Firm Is Embarking On A Probe Into Cerevel Therapeutics Holdings Inc And CERE Shareholders Are Invited To Join

LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.

The Schall Law Firm Is Embarking On A Probe Into Cerevel Therapeutics Holdings Inc And CERE Shareholders Are Invited To Join

CEREVEL (NASDAQ:CERE) STOCK ALERT: Cerevel's $45 Per Share Deal is Being Investigated by BFA Law, Shareholders are Urged to Contact the Firm

NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.

CEREVEL (NASDAQ:CERE) STOCK ALERT: Cerevel's $45 Per Share Deal is Being Investigated by BFA Law, Shareholders are Urged to Contact the Firm

The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Shareholders Of CERE Can Participate

LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.

The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Shareholders Of CERE Can Participate

See News Rankings